These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. Patterson TA; Binienda ZK; Lipe GW; Gillam MP; Slikker W; Sandberg JA Drug Metab Dispos; 1997 Apr; 25(4):453-9. PubMed ID: 9107545 [TBL] [Abstract][Full Text] [Related]
3. 3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. Boudinot FD; Schinazi RF; Gallo JM; McClure HM; Anderson DC; Doshi KJ; Kambhampathi PC; Chu CK AIDS Res Hum Retroviruses; 1990 Feb; 6(2):219-28. PubMed ID: 2328158 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. Balis FM; Pizzo PA; Eddy J; Wilfert C; McKinney R; Scott G; Murphy RF; Jarosinski PF; Falloon J; Poplack DG J Pediatr; 1989 May; 114(5):880-4. PubMed ID: 2715903 [TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of zidovudine administered by continuous infusion in children. Balis FM; Pizzo PA; Murphy RF; Eddy J; Jarosinski PF; Falloon J; Broder S; Poplack DG Ann Intern Med; 1989 Feb; 110(4):279-85. PubMed ID: 2643914 [TBL] [Abstract][Full Text] [Related]
6. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys. Qian MX; Finco TS; Mehta M; Viswanathan CT; Gallo JM J Pharm Sci; 1991 Nov; 80(11):1007-11. PubMed ID: 1815049 [TBL] [Abstract][Full Text] [Related]
8. A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. Mays DC; Dixon KF; Balboa A; Pawluk LJ; Bauer MR; Nawoot S; Gerber N J Pharmacol Exp Ther; 1991 Dec; 259(3):1261-70. PubMed ID: 1762074 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Cretton EM; Schinazi RF; McClure HM; Anderson DC; Sommadossi JP Antimicrob Agents Chemother; 1991 May; 35(5):801-7. PubMed ID: 1854160 [TBL] [Abstract][Full Text] [Related]
10. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Sawchuk RJ; Hedaya MA Pharm Res; 1990 Apr; 7(4):332-8. PubMed ID: 2362907 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of zidovudine in cats. Zhang W; Mauldin JK; Schmiedt CW; Brockus CW; Boudinot FD; McCrackin Stevenson MA Am J Vet Res; 2004 Jun; 65(6):835-40. PubMed ID: 15198225 [TBL] [Abstract][Full Text] [Related]
12. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777 [TBL] [Abstract][Full Text] [Related]
13. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. Hedaya MA; Sawchuk RJ J Pharm Sci; 1989 Sep; 78(9):716-22. PubMed ID: 2585262 [TBL] [Abstract][Full Text] [Related]
14. Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. Trang JM; Prejean JD; James RH; Irwin RD; Goehl TJ; Page JG Drug Metab Dispos; 1993; 21(1):189-93. PubMed ID: 8095218 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Morgan RJ; Newman EM; Sowers L; Scanlon K; Harrison J; Akman S; Leong L; Margolin K; Niland J; Raschko J; Somlo G; Carroll M; Chow W; Tetef M; Hamasaki V; Yen Y; Doroshow JH Cancer Chemother Pharmacol; 2003 Jun; 51(6):459-64. PubMed ID: 12695856 [TBL] [Abstract][Full Text] [Related]
16. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Kong XB; Zhu QY; Vidal PM; Watanabe KA; Polsky B; Armstrong D; Ostrander M; Lang SA; Muchmore E; Chou TC Antimicrob Agents Chemother; 1992 Apr; 36(4):808-18. PubMed ID: 1503443 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of zidovudine following intravenous bolus administration of a novel niosome preparation devoid of cholesterol. Gopinath D; Ravi D; Karwa R; Rao BR; Shashank A; Rambhau D Arzneimittelforschung; 2001 Nov; 51(11):924-30. PubMed ID: 11765596 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. Parang K; Wiebe LI; Knaus EE J Pharm Pharmacol; 1998 Sep; 50(9):989-96. PubMed ID: 9811159 [TBL] [Abstract][Full Text] [Related]
19. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664 [TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]